This is what the founder & CEO Jean-Paul Clozel of Actelion (Switzerland) said at the announcement of the 2015 financial results for the company. And it’s definitely true.
Actelion is the only European born biopharma to have over 1K employees (in fact over 2,547 of them). This is already a big achievement but not their greatest…
For example, in 2015, Actelion made over 2Bn CHF (€1.82Bn) of sales – a growth of core earnings grew by 14% since 2014. All these results have been driven by the excellent sales of Opsumit (25% of the results) and its other historic product Tracleer (bosentan), amounted to 1.2M CHF (€1.09M).
Tracleer however, faces a decrease of 11% in regards to last year because of a ‘sharply’ decreased enrolment of new patients. This is due to an increase competition of generics even though Actelion extended its patent protection in most of the EU countries.
Actelion also got other smaller products approved (all under €100M in total sales) with all products either having stable or decreased sales.